Open Access Repository
Belimumab (Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline)
Download Statistics
Downloads
Downloads per month over past year
Ding, C and Jones, G 2006
, 'Belimumab (Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline)'
, Current Opinion in Investigational Drugs, vol. 7, no. 5
, pp. 464-472
.
![]() |
PDF
belimumab.pdf | Request a copy Full text restricted Available under University of Tasmania Standard License. |
Official URL: http://www.biomedcentral.com/1472-4472/7?issue=5
Abstract
Belimumab, the lead in a series of human monoclonal antibodies against the human protein B-lymphocyte stimulator (BLyS), is under development by Human Genome Sciences, Cambridge Antibody Technology and GlaxoSmithKline for the potential treatment of autoimmune diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). By January 2006, belimumab had completed phase II clinical trials in SLE and RA; a phase III clinical SLE trial is scheduled to begin later this year.
Item Type: | Article |
---|---|
Authors/Creators: | Ding, C and Jones, G |
Journal or Publication Title: | Current Opinion in Investigational Drugs |
ISSN: | 1472-4472 |
Additional Information: | restricted - published by Thompson |
Item Statistics: | View statistics for this item |
Actions (login required)
![]() |
Item Control Page |